Journal Mobile Options
Table of Contents
Vol. 50, No. 6, 2007
Issue release date: February 2008
Section title: Original Paper
Intervirology 2007;50:439–446
(DOI:10.1159/000114718)

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin

A Prospective Randomized Controlled Trial

Takaki S. · Kawakami Y. · Imamura M. · Aikata H. · Takahashi S. · Ishihara H. · Tsuji K. · Aimitsu S. · Kawakami H. · Nakanishi T. · Kitamoto M. · Moriya T. · Satoh K. · Chayama K.
aDepartment of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, bDepartment of Internal Medicine, Chuden Hospital, cDepartment of Internal Medicine, Hiroshima City Asa Hospital, dDepartment of Hepatology, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, and eKawakami Gastroenterology Clinic, Hiroshima; fDepartment of Gastroenterology, Shobara Red Cross Hospital, Shobara; gDepartment of Gastroenterology, Hiroshima Prefectural Hospital, hDepartment of Gastroenterology, Chugoku Rousai Hospital, and iDepartment of Environmetrics and Biometrics, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/17/2007
Accepted: 11/20/2007
Published online: 2/4/2008

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 5

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: http://www.karger.com/INT

Abstract

Objective: To evaluate the efficacy of eicosapentaenoic acid (EPA) against ribavirin (RBV)-associated hemolytic anemia during the first 12 weeks in chronic hepatitis C virus (HCV) combination therapy. Methods: This study was a prospective open-label, randomized controlled trial. 100 HCV patients were randomized to either the EPA group (n = 49) or non-EPA group (n = 51) who received combination therapy with or without EPA. We compared the changes in hemoglobin level and RBV plasma concentrations at week 12 in each group with RBV dose reduction rate and performed multivariate analysis to identify independent variables associated with RBV dose reduction. Results: 8 patients (17%) in the EPA group and 20 patients (29%) in the non-EPA group required RBV dose reduction, respectively. The cumulative RBV reduction rate was significantly lower in the EPA group than in the non-EPA group (p = 0.017), while the decrease of hemoglobin and RBV plasma concentrations from baseline was not significantly different. However, in the multivariate analysis, treatment with EPA showed significant variables for the reduction of RBV dose (odds ratio 3.235, p = 0.023). Conclusion: EPA could prevent the RBV dose reduction during the first 12 weeks in combination therapy, although further large-scale double-blind randomized controlled trials are required.


  

Author Contacts

Shintaro Takaki, Department of Medicine and Molecular Science
Division of Frontier Medical Science, Programs for Biomedical Research
Graduate School of Biomedical Sciences, Hiroshima University
1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551 (Japan)
Tel. +81 82 257 5192, Fax +81 82 257 5194, E-Mail takakiss@hiroshima-u.ac.jp

  

Article Information

Received: April 17, 2007
Accepted after revision: November 20, 2007
Published online: February 4, 2008
Number of Print Pages : 8
Number of Figures : 4, Number of Tables : 5, Number of References : 38

  

Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 50, No. 6, Year 2007 (Cover Date: February 2008)

Journal Editor: Liebert, U.G. (Leipzig)
ISSN: 0300–5526 (Print), eISSN: 1423–0100 (Online)

For additional information: http://www.karger.com/INT


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/17/2007
Accepted: 11/20/2007
Published online: 2/4/2008

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 5

ISSN: 0300-5526 (Print)
eISSN: 1423-0100 (Online)

For additional information: http://www.karger.com/INT


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.